


Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 448-70 PCT US	SERIAL NO. 10/501,678
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANTS Galer et al.	
		FILING DATE July 12, 2005	GROUP ART UNIT 1614



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6008258	12/1999	INTURRISI			

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		2004/022002	03/2004	INTERNATIONAL				
		2000/02545	01/2000	INTERNATIONAL				
		99/36064	07/1999	INTERNATIONAL				
		89/05642	06/1989	INTERNATIONAL				
		97/14415	04/1997	INTERNATIONAL				
		97/33858	09/1997	INTERNATIONAL				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	1.	Olson, Walter et al., "Gabapentin for Parkinsonism: A Double-Blind, Placebo-controlled, Crossover Trial," AM. J. Med. 1997; Vol. 102, Pp. 60-66
	2.	Kleinrok, Zdzislaw et al., "Effect of Combined Gaba-Ergic and Dopaminergic Stimulation on the Action of Some Antiepileptic Drugs in Pentetrazol-induced Convulsions," Pol. J.Pharmacol. Pharm, 1971, 33, 13-23
	3.	Granger, Patrick et al., "Modulation of the γ -Aminobutyric Acid Type A Receptor by the Antiepileptic Drugs Carbamazepine and Phenytoin," Molecular Pharmacology, 47: 1189-1196 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449 [6-4])